CN106459225A - O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途 - Google Patents

O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途 Download PDF

Info

Publication number
CN106459225A
CN106459225A CN201580023307.6A CN201580023307A CN106459225A CN 106459225 A CN106459225 A CN 106459225A CN 201580023307 A CN201580023307 A CN 201580023307A CN 106459225 A CN106459225 A CN 106459225A
Authority
CN
China
Prior art keywords
hpga
oac
pharmaceutically acceptable
acceptable salt
acetylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580023307.6A
Other languages
English (en)
Chinese (zh)
Inventor
Y.倪
M.斯普林格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanomedicine
Original Assignee
Nanomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanomedicine filed Critical Nanomedicine
Publication of CN106459225A publication Critical patent/CN106459225A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN201580023307.6A 2014-05-08 2015-05-08 O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途 Pending CN106459225A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990493P 2014-05-08 2014-05-08
US61/990,493 2014-05-08
PCT/US2015/029979 WO2015172077A1 (en) 2014-05-08 2015-05-08 O-acetylated high molecular weight polygalacturonic acids and their use as vi polysaccharide vaccine

Publications (1)

Publication Number Publication Date
CN106459225A true CN106459225A (zh) 2017-02-22

Family

ID=53190060

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580023307.6A Pending CN106459225A (zh) 2014-05-08 2015-05-08 O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途

Country Status (6)

Country Link
EP (1) EP3140324A1 (ja)
JP (1) JP2017514961A (ja)
CN (1) CN106459225A (ja)
AU (1) AU2015255693A1 (ja)
CA (1) CA2946900A1 (ja)
WO (1) WO2015172077A1 (ja)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691986B2 (en) * 1998-05-13 2010-04-06 Nanotherapeutics, Inc. High molecular weight, low methoxyl pectins, and their production and uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929051A (en) 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691986B2 (en) * 1998-05-13 2010-04-06 Nanotherapeutics, Inc. High molecular weight, low methoxyl pectins, and their production and uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOGUSLAW SZEWCZYK等: ""Immunochemical Properties of Vi Antigen from Salmonella typhi Ty2: Presence of Two Antigenic Determinants"", 《INFECTION AND IMMUNITY》 *
RICHARD G. SCHWEIGER: ""Acetyl Pectates and Their Reactivity with Polyvalent Metal Ions"", 《J. ORG. CHEM.》 *
SHOUSUN C. SZU等: ""Synthesis and Some Immunologic Properties of an O-Acetyl Pectin [Poly(l1->4)-C-D-GalpA]-Protein Conjugate as a Vaccine for Typhoid Fever"", 《INFECTION AND IMMUNITY》 *

Also Published As

Publication number Publication date
CA2946900A1 (en) 2015-11-12
WO2015172077A8 (en) 2016-01-28
WO2015172077A1 (en) 2015-11-12
JP2017514961A (ja) 2017-06-08
EP3140324A1 (en) 2017-03-15
AU2015255693A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
Micoli et al. Vi-CRM197 as a new conjugate vaccine against Salmonella Typhi
Gupta et al. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin
Haughney et al. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles
Theilacker et al. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine
RU2684615C2 (ru) Бактериальная вакцина и способы ее получения
Hitri et al. O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes
JP6166533B2 (ja) ピロリ菌リポ多糖類の外殻エピトープ
Zhang et al. Synthetic glycans and glycomimetics: a promising alternative to natural polysaccharides
KR20120104178A (ko) 면역원성이 개선된 단백질 매트릭스 백신
CN110302375A (zh) 一种糖缀合物及其用途
An et al. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine
Chiu et al. Constructing conjugate vaccine against Salmonella Typhimurium using lipid-A free lipopolysaccharide
Abo et al. Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy
AU678549B2 (en) Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
JP2007524623A (ja) Ｙ群髄膜炎菌ワクチン及びそれらの髄膜炎菌組合せワクチン
CN106459225A (zh) O‑乙酰化高分子量聚半乳糖醛酸及其作为Vi多糖疫苗的用途
An et al. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever
WO2014195880A1 (en) An isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by gram-negative bacteria
Haque et al. S. Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice
Ftacek et al. Immunochemical characterization of synthetic hexa-, octa-and decasaccharide conjugate vaccines for Vibrio cholerae O: 1 Serotype Ogawa with emphasis on antigenic density and chain length
Jossi et al. Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses
Jones Chemistry Manufacturing, Control, and Licensure for Carbohydrate-Based Vaccines
Korcová et al. Immunomodulative properties of conjugates composed of detoxified lipopolysaccharide and capsular polysaccharide of Vibrio cholerae O135 bound to BSA-protein carrier
Ghaderinia et al. Immunogenic Evaluation of MPEG-PCL & PLGA Nanoparticles Containing Klebsiella pneumoniae K2O1 Capsular Antigen in Pulmonary Infection Model of Mice
De Benedetto Characterization of polysaccharide-based vaccines against invasive nontyphoidal Salmonella disease (iNTS)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222